Federal contractors / CELLPHIRE, INC.

Federal contract award

W81XWH20C0030

CRYOPRESERVED PLATELET (CPP) DEVELOPMENT FOR US FDA LICENSURE

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Defense
OfficeARMY MED RES ACQ ACTIVITY
NAICS541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSCAN94 — OTHER MEDICAL - ENGINEERING DEVELOPMENT
Parent award / vehicleNot reported
Set-asideSMALL BUSINESS SET ASIDE - TOTAL
Pricing typeCOST PLUS FIXED FEE
Obligations$70.3M
Current contract value$70.3M
Potential contract value / ceiling$73.6M
Start dateDec 20, 2019
Current end dateOct 31, 2028
Potential end dateOct 31, 2028
Latest award activityApr 14, 2026
Source loadedSep 26, 2026

Funding and modification history

Showing the latest 21 of 21 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Apr 14, 2026P00020$10.4MPHASE III CLINICAL TRIALS
Jan 28, 2026P00019$6.8MPHASE III CLINICAL TRIALS
Nov 25, 2025P00018$-6.8MPHASE III CLINICAL TRIALS
Mar 31, 2025P00017$6.8MPHASE III CLINICAL TRIAL FOR CRYOPERSERVED PLATLETS
Nov 27, 2024P00016$9.1MPHASE II CLINICAL TRIAL
Nov 25, 2024P00015$-2.1KPHASE II CLINICAL TRIAL
Jun 5, 2024P00014$0PHASE II CLINICAL TRIAL
Mar 8, 2024P00013$22.1MPHASE II CLINICAL TRIAL
Oct 11, 2023P00012$1.1MPHASE II CLINICAL TRIAL
Apr 26, 2023P00011$4.8MPHASE II CLINICAL TRIAL
Dec 22, 2022P00010$207.6KPHASE II CLINICAL TRIAL INCREMENTAL FUND CLIN 0001 PER SECTION 711 OF THE 2019 NDAA, USAMRAA TRANSFERRED TO DHA 10/1/2022.
Aug 2, 2022P00009$656.6KCRYOPRESERVED PLATELETS PHASE II CLINICAL TRIAL
May 10, 2022P00008$2.9MPHASE II CLINICAL TRIAL
Jan 6, 2022P00007$0CLINICAL AND REGULATORY MANAGEMENT IN DIRECT SUPPORT OF EVENTUAL FDA APPROVAL OF A CRYOPRESERVED PLATELET (CPP) PRODUCT VIA THE PERFORMANCE OF GOOD CLINICAL PRACTICES (GCP) COMPLIANT PHASE 2 AND 3 CLINICAL TRIALS.
Sep 28, 2021P00006$0PHASE II CLINICAL TRIAL
Apr 2, 2021P00005$3.8MCRYOPRESERVED PLATELETS PHASE II CLINICAL TRIAL
Jan 26, 2021P00004$1.1MCRYOPRESERVED PLATELETS PHASE II CLINICAL TRIAL
Jun 17, 2020P00003$2.8MCRYOPRESERVED PLATELETS PHASE II CLINICAL TRIAL
May 15, 2020P00002$0CRYOPRESERVED PLATELETS PHASE II CLINICAL TRIAL
Feb 28, 2020P00001$2.1MPHASE II CLINICAL TRIAL
Dec 19, 20190$2.6MCRYOPRESERVED PLATELET (CPP) DEVELOPMENT FOR US FDA LICENSURE

Estimated positioning window

Oct 31, 2027 – Apr 30, 2028

Recompete signal:
60/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 60/100. Available recorded signals: 55 points.

Contract end 2028-10-31 (737 days from calculation)
+15 points
4 historical awards in this buyer and category group
+15 points
21 recorded award transactions
+10 points
Latest award action: 2026-04-14
+5 points
Parent award identifier recorded
+0 points
Solicitation identifier recorded
+10 points
Linked official forecast
+0 points
Calculated on
2026-10-25 10:18:04.631876+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Oct 25, 2026.

Research next steps

  1. Check the linked forecast or SAM for a confirmed solicitation and current timing.
  2. Check the stated set-aside against the solicitation and current certifications.
  3. Review the award scope and buyer evidence before making a bid/no-bid decision.